TSLA
特斯拉
-- 436.516 NVDA
英偉達
-- 133.939 PLTR
Palantir
-- 78.870 AMD
美國超微公司
-- 119.840 QUBT
Quantum Computing
-- 16.939 
資訊
巴林塔斯生物完成HBV003慢性乙型肝炎20億第三期臨床試驗招募，並進行前列腺癌PCA001第一期臨床試驗。
• VTP-300正在進行評估，作為慢性乙型肝炎潛在功能性治愈方案的一部分。
• HBV003的中期數據更新預計在2024年第4季。
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide t cells to control disease, announced the completion of enrollment for two clinical trials: HBV003, a Phase 20億clinical trial of VTP-300 in adults with chronic hepatitis b (CHB); and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen (PSA) after definitive local therapy for prostate cancer (i.e., biochemical recurrence).
• HBV003的中期數據更新預計在2024年第4季。
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide t cells to control disease, announced the completion of enrollment for two clinical trials: HBV003, a Phase 20億clinical trial of VTP-300 in adults with chronic hepatitis b (CHB); and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen (PSA) after definitive local therapy for prostate cancer (i.e., biochemical recurrence).
免責聲明：社區由Moomoo Technologies Inc.提供，僅用於教育目的。
更多信息
評論
登錄發表評論